Integrative strategy for improving cancer immunotherapy.
J Mol Med (Berl). 2016.
PMID: 27114349
No abstract available.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1984 | 1 |
| 1996 | 3 |
| 1997 | 1 |
| 1998 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 4 |
| 2009 | 9 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 12 |
| 2013 | 17 |
| 2014 | 12 |
| 2015 | 21 |
| 2016 | 35 |
| 2017 | 45 |
| 2018 | 39 |
| 2019 | 50 |
| 2020 | 88 |
| 2021 | 113 |
| 2022 | 140 |
| 2023 | 187 |
| 2024 | 420 |
| 2025 | 1167 |
| 2026 | 86 |
Search Results
2,275 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Delivery technologies for cancer immunotherapy.
Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z.
Nat Rev Drug Discov. 2019.
PMID: 30622344
Free PMC article.
Review.
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. ...Here, we discuss these research advances, as …
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug appr …
Clinical advances of mRNA vaccines for cancer immunotherapy.
Med. 2025 Jan 10;6(1):100562. doi: 10.1016/j.medj.2024.11.015.
Med. 2025.
PMID: 39798545
Free article.
Review.
The development of mRNA vaccines represents a significant advancement in cancer treatment, with more than 120 clinical trials to date demonstrating their potential across various malignancies, including lung, breast, prostate, melanoma, and more challenging cancers …
The development of mRNA vaccines represents a significant advancement in cancer treatment, with more than 120 clinical trials to date …
Advances and challenges in the treatment of lung cancer.
Biomed Pharmacother. 2023 Dec 31;169:115891. doi: 10.1016/j.biopha.2023.115891. Epub 2023 Nov 16.
Biomed Pharmacother. 2023.
PMID: 37979378
Free article.
Review.
In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for the treatment of lung cancer. This article reviews the cutting-edge developments in the nano drug delivery system, molecular targete …
In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for …
Gastric cancer.
Lancet. 2025 Jun 7;405(10494):2087-2102. doi: 10.1016/S0140-6736(25)00052-2. Epub 2025 May 1.
Lancet. 2025.
PMID: 40319897
Review.
There is increasing implementation of minimally invasive surgical techniques for operable disease and integration of immune checkpoint inhibitors and targeted therapies for advanced stages. Emerging therapies, such as novel targeted treatments and next-generation immuno …
There is increasing implementation of minimally invasive surgical techniques for operable disease and integration of immune checkpoin …
Immunotherapy in Breast Cancer.
Int J Mol Sci. 2024 Jul 9;25(14):7517. doi: 10.3390/ijms25147517.
Int J Mol Sci. 2024.
PMID: 39062758
Free PMC article.
Review.
Breast cancer has traditionally been considered an immunologically "cold" tumor, unresponsive to immunotherapy. ...This has prompted the exploration of new therapeutic approaches to address this trend, offering new therapeutic prospects for breast cancer pati …
Breast cancer has traditionally been considered an immunologically "cold" tumor, unresponsive to immunotherapy. ...This has pr …
Integrative strategy for improving cancer immunotherapy.
J Mol Med (Berl). 2016 May;94(5):485-7. doi: 10.1007/s00109-016-1424-1.
J Mol Med (Berl). 2016.
PMID: 27114349
No abstract available.
Update 2025: Management of Non-Small-Cell Lung Cancer.
Lung. 2025 Mar 25;203(1):53. doi: 10.1007/s00408-025-00801-x.
Lung. 2025.
PMID: 40133478
Free PMC article.
Review.
Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non-small-cell lung cancer (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therap …
Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, the non-small-cell lung cancer …
Multiomics profiling reveals the benefits of gamma-delta (gammadelta) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer.
J Immunother Cancer. 2024 Jan 9;12(1):e008355. doi: 10.1136/jitc-2023-008355.
J Immunother Cancer. 2024.
PMID: 38199610
Free PMC article.
As the cervix is a mucosa-rich tissue, the role of gammadelta T cells in cervical cancer warrants further investigation. METHODS: We employed a multiomics strategy that integrated abundant data from single-cell and bulk transcriptome sequencing, whole exome s …
As the cervix is a mucosa-rich tissue, the role of gammadelta T cells in cervical cancer warrants further investigation. METHODS: We …
Surface glycan targeting for cancer nano-immunotherapy.
J Control Release. 2022 Feb;342:321-336. doi: 10.1016/j.jconrel.2022.01.004. Epub 2022 Jan 5.
J Control Release. 2022.
PMID: 34998918
Review.
Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics approved by the FDA regulate the innate immune system and associated immune cell activity, with immune check inhibitors in particular having t …
Cancer immunotherapy is an emerging therapeutic strategy for cancer treatment. Most of the immunotherapeutics ap …
Targeting the gut microbiota for cancer therapy.
Nat Rev Cancer. 2022 Dec;22(12):703-722. doi: 10.1038/s41568-022-00513-x. Epub 2022 Oct 17.
Nat Rev Cancer. 2022.
PMID: 36253536
Review.
Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of cancer therapy, most notably immunotherapy and its immune-related adverse effects. The poor response to immunotherapy in patients treated with antibiotics supports this i …
Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of cancer therapy, most notably immunotherap …
Cite